{"id":24943,"date":"2021-11-03T01:08:53","date_gmt":"2021-11-03T01:08:53","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?page_id=24943"},"modified":"2025-07-25T11:26:09","modified_gmt":"2025-07-25T01:26:09","slug":"investor-briefing","status":"publish","type":"page","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/","title":{"rendered":"Investor Briefing"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gm5dae9b8 gutentor-module gutentor-container-cover has-image-bg has-custom-bg webca\"><div class=\"grid-container\">\n<h2 class=\"wp-block-heading has-text-align-left fz36 fz30 has-white-color has-text-color has-large-font-size\">Live Investor Briefing<\/h2>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-left has-text-color\" style=\"color:#53d443;font-size:23px\">Prescient Therapeutics (ASX: PTX)<\/h3>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<section id=\"fsz\" class=\"wp-block-gutentor-m4 section-gm85073d2 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gme10e01\" class=\"wp-block-gutentor-m4-col col-gme10e01 gutentor-single-column  grid-lg-7 grid-md-6 grid-12 text-l\"><div id=\"section-gme10e01\" class=\"section-gme10e01 gutentor-col-wrap\">\n<h3 class=\"wp-block-heading border-bottom fz20 has-white-color has-text-color\" style=\"font-size:28px\">Register for an Upcoming Webcast<\/h3>\n\n\n\n<p class=\"has-white-color has-text-color\"><\/p>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">Please join Prescient Therapeutics CEO James McDonnell<\/mark> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">for an investor briefing.<\/mark><\/p>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\"><strong>In this session, James will discuss:<\/strong><\/mark><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-white-color has-text-color has-link-color wp-elements-0f2605ee29a094ca455280735644f654\">Our outstanding PTX-100 Phase 1b results including the <strong>64% tumor halt or reduction <\/strong>for a cancer considered a \u2018death sentence\u2019.<\/li>\n\n\n\n<li class=\"has-white-color has-text-color has-link-color wp-elements-6ebf143812b7296cc862f163152e7941\">The <strong>designations received from the FDA <\/strong>which could allow us to head toward a US$1.8bn market after Phase 2.<\/li>\n\n\n\n<li class=\"has-white-color has-text-color has-link-color wp-elements-0516572084ffed2bf93252e44ef4d298\">Why their technology could apply to <strong>22% of all cancer cases <\/strong>(Lung, Pancreas, Ovarian etc.)<\/li>\n<\/ul>\n\n\n\n<p class=\"has-white-color has-text-color\">This is a live and interactive online session, and participants are encouraged to ask questions<mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-white-color\">.&nbsp;<\/mark><strong>Spots are limited, so secure yours today.<\/strong><br><br><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-light-green-cyan-color\">Can\u2019t make this time, register to receive the replay.<\/mark><\/strong><br><br><\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm3a7ae5\" class=\"wp-block-gutentor-m4-col col-gm3a7ae5 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm3a7ae5\" class=\"section-gm3a7ae5 gutentor-col-wrap\">        <div class=\"enouvo-form  show-text \">\n            <h4 class=\"form-title\" style=\"color:#ffce06\">Attend the session<\/h4>            <!--[if lte IE 8]>\n            <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2-legacy.js\"><\/script>\n            <![endif]-->\n            <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2.js\"><\/script>\n            <script data-hubspot-rendered=\"true\">hbspt.forms.create({\n                portalId: \"7664250\",\n                formId: \"b50bfb3e-c115-4fd8-b074-632f5c074cef\",\n                goToWebinarWebinarKey: '',\n                    onFormSubmitted: function($form) {\n                        jQuery('.hypelinkbkt, .byclick').hide();\n                    }\n            });<\/script>\n                        \n                            <a id=\"hypelinkbkt\" class=\"hypelinkbkt\" target=\"blank\" rel=\"noopener noreferrer\">What is a 708 investor?<\/a>\n            <div class=\"byclick\"><p>By clicking submit, I agree to the terms of the <a href=\"https:\/\/reachmarkets.com.au\/financial-services-guide\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Reach Markets Financial Services Guide<\/strong><\/a>\u00a0that includes the <a href=\"https:\/\/reachmarkets.com.au\/privacy-reach\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Privacy Statement.<\/strong><\/a> Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.<\/p><\/div>\n                                    <\/div>\n            \n        \n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n\n\n\n<section id=\"gm90dd43c\" class=\"wp-block-gutentor-m3 alignwide section-gm90dd43c gutentor-module gutentor-container-cover custom-fullwidth author\"><div class=\"grid-container\">\n<section id=\"gm993bb81\" class=\"wp-block-gutentor-m4 section-gm993bb81 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm0c37e0\" class=\"wp-block-gutentor-m4-col col-gm0c37e0 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm0c37e0\" class=\"section-gm0c37e0 gutentor-col-wrap\">\n<h4 class=\"wp-block-heading fz30 has-text-color\" style=\"color:#012850;font-size:25px\">Featured Speaker<\/h4>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm70c8930\" class=\"wp-block-gutentor-m4 section-gm70c8930 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gma3f290\" class=\"wp-block-gutentor-m4-col col-gma3f290 gutentor-single-column  grid-lg-3 grid-md-5 grid-12\"><div id=\"section-gma3f290\" class=\"section-gma3f290 gutentor-col-wrap\">\n<div class=\"wpb_wrapper\"><p><img decoding=\"async\" class=\"ceo-img\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png\" alt=\"James McDonnell\"><\/p><\/div>\n\n\n\n<style>\n.enouvo-form .form-title {\n    font-size: 24px;\n}\n.border-bottom{border-bottom: 7px solid #53D443;\n    display: inline-block;\n    padding-bottom: 10px;\n    margin-bottom: 15px;}\n.wpb_wrapper p{\nmargin-top: 0px;}\n.author .grid-container{\nwidth:1170px;\nmax-width: 100%;\n}\n.author{\n    padding-top: 10px;\n    background: #fff;\n    padding-bottom: 45px;\n    max-width: 100vw;\n    width: 100vw;\n    left: 50%;\n    margin-left: -50vw;\n}\n.ceo-img {\n    width: 100%;\n    border-radius: 50%;\nfilter: drop-shadow(4px 4px 20px rgba(0, 0, 0, 0.25));\n}\n.infor {\n    color: #fff;\n    overflow: hidden;\n    padding-top: 0px;\n    padding-left: 20px;\n}\n.infor h3 {\n    font-weight: bold;\n    margin-bottom: 10px;\n    color: #fff;\n    font-size: 25px;\n}\n.infor p {\n    font-size: 16px !important;\n}\n@media only screen and (max-width: 1024px){\n.infor h3 {\n    font-size: 16px;\n}\n}\n\n.enouvo-form .byclick strong {\n    color: #203865;\n}\n.custom-bg{    background-image: linear-gradient( rgba(0, 0, 0, .56), rgba(0, 0, 0, .56)), url(\/wp-content\/uploads\/2021\/04\/bg-ibv-min.jpg);}div#section-gmecaa61 { color: #fff; font-size: 16px!important; }div#col-gmecaa61 ul {\n    list-style: disc;\n    padding-left: 40px;\n    font-size: 16px;\n}\n\ndiv#col-gmecaa61 li {\n    margin-bottom:10px;\n}div#col-gmecaa61 ul { margin-bottom: 16px; } div#col-gmecaa61 p { line-height: 28.8px!important; margin-bottom: 16px; }h4.form-title { font-size: 24px; color: #3f4346!important; line-height: 34px; text-align: center; } .enouvo-form.show-text { background: rgba(255,255,255,.8); border-radius:6px; }.form-control, .hbspt-form input[type=email], .hbspt-form input[type=text], input[type=number], textarea, input[type=tel], select { border: 1px solid #ccd0d4!important; max-height: 45px !important; color: #212529 !important; font-family: \"Montserrat\",sans-serif; }.hbspt-form input.hs-button.primary.large { color: #3F4346!important; border: none; background: #FECC31!important; -webkit-transition: all .2s ease-in-out; transition: all .2s ease-in-out; text-transform: capitalize; font-size: 16px!important; }.hbspt-form input.hs-button.primary.large:hover { opacity: 0.7; } .enouvo-form .hypelinkbkt, .enouvo-form .byclick, .enouvo-form .byclick strong { color: #3F4346; } input:focus, button:focus, textarea:focus, select:focus { border-color: #000; } a#hypelinkbkt:hover { opacity: 0.7; }.hbspt-form select:focus, .hbspt-form input[type=text]:focus, .hbspt-form input[type=tel]:focus, .hbspt-form input[type=email]:focus, .hbspt-form input[type=number]:focus { border-color: #ccd0d4!important; } .hbspt-form .field { margin-bottom: 10px; } .form-control, .hbspt-form input[type=email], .hbspt-form input[type=text], input[type=number], textarea, input[type=tel], select { margin-bottom: 0; }.author {  }.text-l ul { list-style: disc; padding-left: 25px; color: #fff; } .text-l ul li { margin-bottom: 15px; }.enouvo-form .form-title { color: #ffce06!important; text-align: left; } .enouvo-form.show-text { background: #fff; } .author { padding-top: 10px; padding-bottom: 45px; } div#section-gm8f7e98 { font-size: 15px; } section#fsz p, section#fsz li { font-size: 16px; } .enouvo-form .hypelinkbkt { color: #ffce06; }.form-sidebar .hbspt-form {\n    margin-top: 0px!important;\n}\n<\/style>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmc3788c\" class=\"wp-block-gutentor-m4-col col-gmc3788c gutentor-single-column  grid-lg-9 grid-md-7 grid-12 bioa\"><div id=\"section-gmc3788c\" class=\"section-gmc3788c gutentor-col-wrap\">\n<h3 class=\"wp-block-heading has-text-color\" style=\"color:#0089c4;font-size:32px\">James McDonnell<\/h3>\n\n\n\n<p class=\"has-black-color has-text-color has-normal-font-size\">CEO<\/p>\n\n\n\n<p>James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.<\/p>\n<p>Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company\u2019s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.<\/p>\n<p>James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.<\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm3f7aea1\" class=\"wp-block-gutentor-m4 section-gm3f7aea1 gutentor-module gutentor-advanced-columns d-none\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm71f245\" class=\"wp-block-gutentor-m4-col col-gm71f245 gutentor-single-column  grid-lg-3 grid-md-5 grid-12\"><div id=\"section-gm71f245\" class=\"section-gm71f245 gutentor-col-wrap\">\n<div class=\"wpb_wrapper\"><p><img decoding=\"async\" class=\"ceo-img\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Rebecca-Lim.jpg\" alt=\"Dr Rebecca Lim\"><\/p><\/div>\n\n\n\n<style>\n.enouvo-form .form-title {\n    font-size: 24px;\n}\n.border-bottom{border-bottom: 7px solid #53D443;\n    display: inline-block;\n    padding-bottom: 10px;\n    margin-bottom: 15px;}\n.wpb_wrapper p{\nmargin-top: 0px;}\n.author .grid-container{\nwidth:1170px;\nmax-width: 100%;\n}\n.author{\n    padding-top: 10px;\n    background: #fff;\n    padding-bottom: 45px;\n    max-width: 100vw;\n    width: 100vw;\n    left: 50%;\n    margin-left: -50vw;\n}\n.ceo-img {\n    width: 100%;\n    border-radius: 50%;\nfilter: drop-shadow(4px 4px 20px rgba(0, 0, 0, 0.25));\n}\n.infor {\n    color: #fff;\n    overflow: hidden;\n    padding-top: 0px;\n    padding-left: 20px;\n}\n.infor h3 {\n    font-weight: bold;\n    margin-bottom: 10px;\n    color: #fff;\n    font-size: 25px;\n}\n.infor p {\n    font-size: 16px !important;\n}\n@media only screen and (max-width: 1024px){\n.infor h3 {\n    font-size: 16px;\n}\n}\n\n.enouvo-form .byclick strong {\n    color: #203865;\n}\n.custom-bg{    background-image: linear-gradient( rgba(0, 0, 0, .56), rgba(0, 0, 0, .56)), url(\/wp-content\/uploads\/2021\/04\/bg-ibv-min.jpg);}div#section-gmecaa61 { color: #fff; font-size: 16px!important; }div#col-gmecaa61 ul {\n    list-style: disc;\n    padding-left: 40px;\n    font-size: 16px;\n}\n\ndiv#col-gmecaa61 li {\n    margin-bottom:10px;\n}div#col-gmecaa61 ul { margin-bottom: 16px; } div#col-gmecaa61 p { line-height: 28.8px!important; margin-bottom: 16px; }h4.form-title { font-size: 24px; color: #3f4346!important; line-height: 34px; text-align: center; } .enouvo-form.show-text { background: rgba(255,255,255,.8); border-radius:6px; }.form-control, .hbspt-form input[type=email], .hbspt-form input[type=text], input[type=number], textarea, input[type=tel], select { border: 1px solid #ccd0d4!important; max-height: 45px !important; color: #212529 !important; font-family: \"Montserrat\",sans-serif; }.hbspt-form input.hs-button.primary.large { color: #3F4346!important; border: none; background: #FECC31!important; -webkit-transition: all .2s ease-in-out; transition: all .2s ease-in-out; text-transform: capitalize; font-size: 16px!important; }.hbspt-form input.hs-button.primary.large:hover { opacity: 0.7; } .enouvo-form .hypelinkbkt, .enouvo-form .byclick, .enouvo-form .byclick strong { color: #3F4346; } input:focus, button:focus, textarea:focus, select:focus { border-color: #000; } a#hypelinkbkt:hover { opacity: 0.7; }.hbspt-form select:focus, .hbspt-form input[type=text]:focus, .hbspt-form input[type=tel]:focus, .hbspt-form input[type=email]:focus, .hbspt-form input[type=number]:focus { border-color: #ccd0d4!important; } .hbspt-form .field { margin-bottom: 10px; } .form-control, .hbspt-form input[type=email], .hbspt-form input[type=text], input[type=number], textarea, input[type=tel], select { margin-bottom: 0; }.author {  }.text-l ul { list-style: disc; padding-left: 25px; color: #fff; } .text-l ul li { margin-bottom: 15px; }.enouvo-form .form-title { color: #ffce06!important; text-align: left; } .enouvo-form.show-text { background: #fff; } .author { padding-top: 10px; padding-bottom: 45px; } div#section-gm8f7e98 { font-size: 15px; } section#fsz p, section#fsz li { font-size: 16px; } .enouvo-form .hypelinkbkt { color: #ffce06; }.form-sidebar .hbspt-form {\n    margin-top: 0px!important;\n}\n<\/style>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm07409d\" class=\"wp-block-gutentor-m4-col col-gm07409d gutentor-single-column  grid-lg-9 grid-md-7 grid-12 bioa\"><div id=\"section-gm07409d\" class=\"section-gm07409d gutentor-col-wrap\">\n<h3 class=\"wp-block-heading has-text-color\" style=\"color:#0089c4;font-size:32px\">Dr Rebecca Lim<\/h3>\n\n\n\n<p class=\"has-black-color has-text-color has-normal-font-size\">Senior Vice President of Scientific Affairs<\/p>\n\n\n\n<p><span style=\"color: #000; font-size: 16px; margin-top: 21px; display: block;\">Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.<\/span><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n<div class=\"form-sidebar\"><a class=\"closes\" style=\"cursor: pointer;\"><img decoding=\"async\" src=\"https:\/\/prescienttherapeutics-rebuild.investorportal.com.au\/wp-content\/uploads\/2022\/07\/close-btn.svg\"><\/a><div style=\"padding: 0 0 0 0; position: relative;\">\r\n<h2 class=\"the-latest-news\" style=\"color: #0089C4; text-align: left; font-size: 24px!important; margin-bottom: 5px;\">Receive email updates<\/h2>\r\n\r\n<!-- Hotjar Tracking Code for https:\/\/template.reachmarkets.com.au\/investorportal\/ --> <script> (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2736440,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https:\/\/static.hotjar.com\/c\/hotjar-','.js?sv='); <\/script> <!--[if lte IE 8]> <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2-legacy.js\"><\/script> <![endif]--> <script  charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2.js\"><\/script> <script> hbspt.forms.create({ region: \"na1\", portalId: \"7664250\", formId: \"8be09ab6-f2b3-484c-8108-42cd66e3980d\", formInstanceId: \"slide\", onFormSubmitted: function($form) { jQuery('.byclick').hide(); gtag_report_conversion('#'); jQuery('.the-latest-news').text('Receive email updates'); } }); <\/script><a id=\"hypelinkbkt\" class=\"hypelinkbkt\" style=\"font-weight: 700; font-size: 14px;\" target=\"blank\" rel=\"noopener noreferrer\">What is a 708 investor?<\/a><p class=\"byclick\" style=\"font-size: 14px !important;margin-bottom: 0px;\">By submitting this form, I agree to the terms of the&nbsp;<a class=\"md-opjjpmhoiojifppkkcdabiobhakljdgm_doc\" href=\"https:\/\/reachmarkets.com.au\/financial-services-guide\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong style=\"font-size: 14px !important;\">Reach Markets Financial Services Guide<\/strong><\/a>&nbsp;that includes the&nbsp;<a class=\"md-opjjpmhoiojifppkkcdabiobhakljdgm_doc\" href=\"https:\/\/reachmarkets.com.au\/privacy-reach\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong style=\"font-size: 14px !important;\">Privacy Statement<\/strong><\/a>. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.<\/p>\r\n<\/div>\r\n<\/div><\/div>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":30240,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-24943","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investor Briefing - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investor Briefing - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T01:26:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\",\"name\":\"Investor Briefing - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png\",\"datePublished\":\"2021-11-03T01:08:53+00:00\",\"dateModified\":\"2025-07-25T01:26:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png\",\"width\":300,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Briefing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investor Briefing - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Investor Briefing - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/","og_site_name":"PTX Therapeutics","article_modified_time":"2025-07-25T01:26:09+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/","name":"Investor Briefing - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png","datePublished":"2021-11-03T01:08:53+00:00","dateModified":"2025-07-25T01:26:09+00:00","breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/James.png","width":300,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Investor Briefing"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/24943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=24943"}],"version-history":[{"count":238,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/24943\/revisions"}],"predecessor-version":[{"id":31159,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/24943\/revisions\/31159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/30240"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=24943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}